• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

量子 pBac:一种高效、大容量的基于 piggyBac 的基因整合载体系统,用于释放基因治疗的潜力。

Quantum pBac: An effective, high-capacity piggyBac-based gene integration vector system for unlocking gene therapy potential.

机构信息

GenomeFrontier Therapeutics, Inc, New Taipei City, Taiwan ROC.

Division of Hematology, Chang Gung Medical Foundation, Taipei City, Taiwan ROC.

出版信息

FASEB J. 2023 Sep;37(9):e23108. doi: 10.1096/fj.202201654R.

DOI:10.1096/fj.202201654R
PMID:37534940
Abstract

Recent advances in gene therapy have brought novel treatment options for cancer. However, the full potential of this approach has yet to be unlocked due to the limited payload capacity of commonly utilized viral vectors. Virus-free DNA transposons, including piggyBac, have the potential to obviate these shortcomings. In this study, we improved a previously modified piggyBac system with superior transposition efficiency. We demonstrated that the internal domain sequences (IDS) within the 3' terminal repeat domain of hyperactive piggyBac (hyPB) donor vector contain dominant enhancer elements. Plasmid-free donor vector devoid of IDS was used in conjunction with a helper plasmid expressing Quantum PBase™ v2 to generate an optimal piggyBac system, Quantum pBac™ (qPB), for use in T cells. qPB outperformed hyPB in CD20/CD19 CAR-T production in terms of performance as well as yield of the CAR-T cells produced. Furthermore, qPB also produced CAR-T cells with lower donor-associated variabilities compared to lentiviral vector. Importantly, qPB yielded mainly CD8 CAR-T cells, and the qPB-produced CAR-T cells effectively eliminated CD20/CD19-expressing tumor cells both in vitro and in vivo. Our findings confirm qPB as a promising virus-free vector system with an enhanced payload capacity to incorporate multiple genes. This highly efficient and potentially safe system will be expected to further advance gene therapy applications.

摘要

基因治疗的最新进展为癌症带来了新的治疗选择。然而,由于常用病毒载体的载物能力有限,这种方法的全部潜力尚未被挖掘出来。无病毒 DNA 转座子,包括 piggyBac,有可能克服这些缺点。在这项研究中,我们改进了以前具有更高转座效率的改良 piggyBac 系统。我们证明了在超活性 piggyBac(hyPB)供体载体的 3'末端重复序列内的内部结构域序列(IDS)包含主要的增强子元件。无 IDS 的无质粒供体载体与表达 Quantum PBase™ v2 的辅助质粒一起使用,产生了用于 T 细胞的最佳 piggyBac 系统 Quantum pBac™(qPB)。qPB 在 CD20/CD19 CAR-T 的生产性能和产量方面优于 hyPB。此外,与慢病毒载体相比,qPB 还产生了具有更低供体相关变异性的 CAR-T 细胞。重要的是,qPB 主要产生 CD8 CAR-T 细胞,qPB 产生的 CAR-T 细胞在体外和体内均能有效消除表达 CD20/CD19 的肿瘤细胞。我们的研究结果证实了 qPB 作为一种具有增强载物能力的有前途的无病毒载体系统,可整合多个基因。这个高效且潜在安全的系统有望进一步推动基因治疗的应用。

相似文献

1
Quantum pBac: An effective, high-capacity piggyBac-based gene integration vector system for unlocking gene therapy potential.量子 pBac:一种高效、大容量的基于 piggyBac 的基因整合载体系统,用于释放基因治疗的潜力。
FASEB J. 2023 Sep;37(9):e23108. doi: 10.1096/fj.202201654R.
2
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.使用基于 Quantum pBac 的 CAR-T 工程系统制造靶向 CD20/CD19 的 iCasp9 可调节性 CAR-TSCM 细胞。
PLoS One. 2024 Aug 27;19(8):e0309245. doi: 10.1371/journal.pone.0309245. eCollection 2024.
3
CAR T Cell Generation by Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions.通过从线性狗骨状DNA载体转座产生CAR T细胞需要转座子DNA侧翼区域。
Mol Ther Methods Clin Dev. 2020 Jan 16;17:359-368. doi: 10.1016/j.omtm.2019.12.020. eCollection 2020 Jun 12.
4
Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.piggyBac介导的CD19特异性T细胞对难治性费城染色体阳性急性淋巴细胞白血病的抗白血病效力
Cytotherapy. 2014 Sep;16(9):1257-69. doi: 10.1016/j.jcyt.2014.05.022.
5
Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.转座子介导的源自 CD45RA 阳性外周血单个核细胞的嵌合抗原受体 T 细胞具有强大且持久的抗白血病功能。
Front Immunol. 2022 Jan 27;13:770132. doi: 10.3389/fimmu.2022.770132. eCollection 2022.
6
piggyBac transposon system modification of primary human T cells.原代人T细胞的piggyBac转座子系统修饰
J Vis Exp. 2012 Nov 5(69):e4235. doi: 10.3791/4235.
7
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.利用 piggyBac 转座子/转座酶系统生成针对 CD19 的 T 细胞用于治疗 B 细胞恶性肿瘤。
Hum Gene Ther. 2010 Apr;21(4):427-37. doi: 10.1089/hum.2009.114.
8
Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.基于微型环状DNA的嵌合抗原受体(CAR)T细胞工程
Recent Results Cancer Res. 2016;209:37-50. doi: 10.1007/978-3-319-42934-2_3.
9
Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.酶促产生的piggyBac转座子载体,用于高效非病毒生产CD19特异性嵌合抗原受体T细胞。
Mol Ther Methods Clin Dev. 2021 Aug 26;23:119-127. doi: 10.1016/j.omtm.2021.08.006. eCollection 2021 Dec 10.
10
Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in Transposon-Engineered T Cells.转座子工程改造的T细胞中抗CD19嵌合抗原受体的表达增强
Mol Ther Methods Clin Dev. 2017 Dec 22;8:131-140. doi: 10.1016/j.omtm.2017.12.003. eCollection 2018 Mar 16.

引用本文的文献

1
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.当前基于非病毒的嵌合抗原受体T细胞制造策略。
Int J Mol Sci. 2024 Dec 21;25(24):13685. doi: 10.3390/ijms252413685.
2
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.使用基于 Quantum pBac 的 CAR-T 工程系统制造靶向 CD20/CD19 的 iCasp9 可调节性 CAR-TSCM 细胞。
PLoS One. 2024 Aug 27;19(8):e0309245. doi: 10.1371/journal.pone.0309245. eCollection 2024.
3
Transposase N-terminal phosphorylation and asymmetric transposon ends inhibit piggyBac transposition in mammalian cells.
转座酶 N 端磷酸化和不对称转座子末端抑制哺乳动物细胞中的 piggyBac 转座。
Nucleic Acids Res. 2022 Dec 9;50(22):13128-13142. doi: 10.1093/nar/gkac1191.